Skip to content
DataLookout
Menu

VitaStemNCT06508099

Vitamin A and D Supplementation in Allogeneic HCT

StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 16 words Show 5 more changesShow less
    • Enrollment closed, study ongoing
    • Primary completion date changed from estimate of May 2026 to Nov 17, 2026
    • Study completion pushed from May 2027 to Nov 17, 2027
    • Secondary endpoints: details revised at 1 of 9 entries
    • Site details revised
  2. Notable Eligibility criteria shortened, about 1 word
    • Secondary endpoints: details revised at 1 of 9 entries
    • Study description revised
    • Study title expanded, about 1 word
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Cumulative incidence of gastrointestinal acute GVHD
Timeframe: 125 days

Secondary (9)

Incidence of HSCT-associated adverse events
Infectious complications
Overall survival
Event-free survival
Overall cumulative incidence of acute GVHD grade II-IV
Show 4 moreShow less
Incidence of moderate and severe chronic GVHD
Non-relapse mortality analysis
GVHD-relapse-free survival analysis
Cumulative incidence of primary and secondary graft failure

Arms and interventions

Vitamin supplementationExperimental

vitamin A 300 000 IU and vitamin D 100 000 IU on days -14 to -8 before transplantation

Routine careNo intervention

Routine care

Drugs: Vitamin A, Vitamin D3

Sites

1 site in 1 country

  • RM Gorbacheva Research InstituteSaint Petersburg, Russia